Triveni Bio
Develops novel antibody treatments for immunological and inflammatory disorders
$65MSeries C
Role not disclosedDT
Deep Track Capital
Activity from announced rounds
Activity in this selectionSeries C+
Deep Track Capital is a life-sciences investor identified by Draig Therapeutics and Superluminal Medicines.
Recorded funding activity
Superluminal combines structural biology, protein dynamics, machine learning and experiments to discover small-molecule medicines. Draig develops neuropsychiatric treatments, while Triveni works on antibodies for immunological and inflammatory disorders. These company relationships give context to the recorded financings.
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $173M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionTerremoto Biosciences
Develops highly targeted, small molecule medicines for cancer and rare diseases
$108MSeries C
Role not disclosed